288 related articles for article (PubMed ID: 31664753)
1. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report.
Sklover L; Nielson C; De Benedetto A
Dermatol Ther; 2019 Nov; 32(6):e13144. PubMed ID: 31664753
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab for atopic dermatitis: evidence to date.
Rodrigues MA; Nogueira M; Torres T
G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
4. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
[TBL] [Abstract][Full Text] [Related]
6. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
7. Development of alopecia in patients treated with dupilumab.
Maloney NJ; Worswick S; Cheng K
Dermatol Ther; 2019 May; 32(3):e12869. PubMed ID: 30834653
[No Abstract] [Full Text] [Related]
8. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report.
Giavina-Bianchi MH; Giavina-Bianchi P; Rizzo LV
Einstein (Sao Paulo); 2019 Jul; 17(4):eRC4599. PubMed ID: 31291386
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.
Ordóñez-Rubiano MF; Campo I; Casas M
Dermatol Ther; 2020 Nov; 33(6):e14172. PubMed ID: 32779378
[No Abstract] [Full Text] [Related]
10. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for treatment of atopic dermatitis.
Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
[TBL] [Abstract][Full Text] [Related]
12. Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis.
Lynde CW; Bergman J; Fiorillo L; Guenther L; Keddy-Grant J; Landells I; Marcoux D; Ramien M; Rehmus W
J Cutan Med Surg; 2019; 23(3_suppl):3S-13S. PubMed ID: 30965012
[TBL] [Abstract][Full Text] [Related]
13. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological management of atopic dermatitis in the elderly.
Howell AN; Ghamrawi RI; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 May; 21(7):761-771. PubMed ID: 32100586
[TBL] [Abstract][Full Text] [Related]
15. A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial.
Licari A; Ruffinazzi G; DE Filippo M; Castagnoli R; Marseglia A; Agostinis F; Puviani M; Milani M; Marseglia GL
Minerva Pediatr; 2017 Dec; 69(6):470-475. PubMed ID: 29181960
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
[TBL] [Abstract][Full Text] [Related]
17. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
19. Common Skin Conditions in Children and Adolescents: Atopic and Seborrheic Dermatitis.
Zha M; Usatine R
FP Essent; 2024 Jun; 541():27-38. PubMed ID: 38896828
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation review: dupilumab in atopic dermatitis.
Hamilton JD; Ungar B; Guttman-Yassky E
Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
